Dr. Bryant is the Director of the Laboratory of Addiction Genetics. Dr. Bryant’s research program is focused on determining the genetic basis of behavioral and molecular traits relevant to substance dependence in mice. The ultimate goal is to improve our understanding of the neurobiological mechanisms of addiction and to translate these findings toward treatment and prevention strategies in humans. A current focus is to determine the genetic basis of the rewarding properties of opioids in mice by combining quantitative trait locus (QTL) analysis of behavior and gene expression in genetic reference populations that yield high resolution QTLs. This multi-pronged approach to gene mapping will accelerate the nomination of candidate genes for validation via direct gene targeting. A separate focus with regard to functional characterization of candidate genes is the dissection of the hypothesized opposing roles of casein kinase-1 (CK-1) isoforms in regulating dopaminergic signaling and the motivational properties of drugs of abuse. Last, Dr. Bryant has a longstanding interest in deciphering the neurobiological basis of the “placebo effect”, a phenomenon that has been hypothesized to be mediated by the reward expectation. He plans to develop and apply a forward genetic analysis toward Pavlovian conditioning mouse models across a variety of conditions that are notoriously sensitive to the placebo effect, including pain, anxiety, depression, and Parkinson’s Disease.
- Director, Laboratory of Addiction Genetics, Boston University School of Medicine
- University of California, Los Angeles, PhD
- University of Illinois, BS
- Published on 11/20/2017
Apicco DJ, Ash PEA, Maziuk B, LeBlang C, Medalla M, Al Abdullatif A, Ferragud A, Botelho E, Ballance HI, Dhawan U, Boudeau S, Cruz AL, Kashy D, Wong A, Goldberg LR, Yazdani N, Zhang C, Ung CY, Tripodis Y, Kanaan NM, Ikezu T, Cottone P, Leszyk J, Li H, Luebke J, Bryant CD, Wolozin B. Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat Neurosci. 2018 Jan; 21(1):72-80. PMID: 29273772.
- Published on 7/6/2017
Goldberg LR, Kirkpatrick SL, Yazdani N, Luttik KP, Lacki OA, Keith Babbs R, Jenkins DF, Evan Johnson W, Bryant CD. Casein kinase 1-epsilon deletion increases mu opioid receptor-dependent behaviors and binge eating1. Genes Brain Behav. 2017 Sep; 16(7):725-738. PMID: 28594147.
- Published on 10/25/2016
Kirkpatrick SL, Goldberg LR, Yazdani N, Babbs RK, Wu J, Reed ER, Jenkins DF, Bolgioni AF, Landaverde KI, Luttik KP, Mitchell KS, Kumar V, Johnson WE, Mulligan MK, Cottone P, Bryant CD. Cytoplasmic FMR1-Interacting Protein 2 Is a Major Genetic Factor Underlying Binge Eating. Biol Psychiatry. 2017 May 01; 81(9):757-769. PMID: 27914629.
- Published on 7/1/2016
Young EE, Bryant CD, Lee SE, Peng X, Cook B, Nair HK, Dreher KJ, Zhang X, Palmer AA, Chung JM, Mogil JS, Chesler EJ, Lariviere WR. Systems genetic and pharmacological analysis identifies candidate genes underlying mechanosensation in the von Frey test. Genes Brain Behav. 2016 Jul; 15(6):604-15. PMID: 27231153.
- Published on 4/11/2016
Yazdani N, Shen Y, Johnson WE, Bryant CD. Striatal transcriptome analysis of a congenic mouse line (chromosome 11: 50-60Mb) exhibiting reduced methamphetamine sensitivity. Genom Data. 2016 Jun; 8:77-80. PMID: 27222804.
- Published on 1/1/2016
Bryant CD, Yazdani N. RNA-binding proteins, neural development and the addictions. Genes Brain Behav. 2016 Jan; 15(1):169-86. PMID: 26643147.
- Published on 12/10/2015
Yazdani N, Parker CC, Shen Y, Reed ER, Guido MA, Kole LA, Kirkpatrick SL, Lim JE, Sokoloff G, Cheng R, Johnson WE, Palmer AA, Bryant CD. Hnrnph1 Is A Quantitative Trait Gene for Methamphetamine Sensitivity. PLoS Genet. 2015 Dec; 11(12):e1005713. PMID: 26658939.
- Published on 1/12/2015
Kirkpatrick SL, Bryant CD. Behavioral architecture of opioid reward and aversion in C57BL/6 substrains. Front Behav Neurosci. 2014; 8:450. PMID: 25628547.
- Published on 4/1/2014
Zhou L, Bryant CD, Loudon A, Palmer AA, Vitaterna MH, Turek FW. The circadian clock gene Csnk1e regulates rapid eye movement sleep amount, and nonrapid eye movement sleep architecture in mice. Sleep. 2014; 37(4):785-93, 793A-793C. PMID: 24744456.
- Published on 1/1/2014
Zhou L, Bryant CD, Loudon A, Palmer AA, Holz Vilaterna M, Turek FW. The circadian clock gene Csnk1e regulates rapid eye movement sleep amount, and nonrapid eye movement sleep architecture in mice. Sleep. 2014; 37(4):785-93. PMID: 25025121.
View 18 more publications: View full profile at BUMC